and new-to-class. The majority
(80 percent) of Shire’s annual
R&D expenditure is channeled
into rare diseases. Today, our rare
disease pipeline is more robust and
focused, following the combination
of Shire and Baxalta. This means
that we can benefit from the best
of both companies and build
a nimble, performance-driven
organisation with a collaborative
approach and the patient at the
centre of everything we do. There
is an urgent need for the Indian
healthcare system to be more
supportive of innovations that make
a difference to the lives of patients
with rare diseases.
through meaningful partnerships
that bring together policy makers,
patient bodies, patient communities
and other stakeholders around
a common agenda, promoting
awareness and accessibility to
therapies.
Is the company also
strengthening its R&D base?
Globally we have 40 programs
in our clinical pipeline, of which
80 percent in rare diseases and
more than 10 in Phase III. We are
focusing on developing therapies
that are first-in-class, best-in-class-
Please share your outlook for
the company’s future in India?
Shire strives to support patients
with rare diseases and other
specialized conditions, and our
strategy is to create and grow
long-term value on the basis on
improved diagnosis and through
providing high impact medicines
and therapies. We believe our
commitment to advancing
innovation means that we are
making a significant contribution to
society through the positive impact
we have on the lives of patients and
their families and caregivers.
BIOVOICENEWS.COM
45